Magnesium and Cancer: What Is the Connection?

Magnesium is involved in cancer at multiple levels, from helping repair damaged DNA to influencing how the immune system attacks tumors, and population studies consistently link lower magnesium intake with modestly higher rates of certain cancers. The relationship is not as simple as “take more magnesium, get less cancer,” though. The mineral interacts with other nutrients, behaves differently across cancer types, and plays a surprisingly important role during cancer treatment itself. What the research reveals is a mineral whose fingerprints show up across nearly every stage of the disease.

How Magnesium Protects DNA

Your body uses magnesium in nearly every enzymatic system that processes DNA. It is not just a generic helper. Magnesium acts as a cofactor in the three main DNA repair pathways: nucleotide excision repair, base excision repair, and mismatch repair. These are the systems that catch and fix damage caused by environmental exposures, normal metabolic byproducts, and copying errors during cell division. When magnesium is scarce, those repair systems falter, and unrepaired mutations accumulate.¹ Because cancer ultimately begins with DNA mutations that escape repair, the logic connecting magnesium deficiency to cancer risk is straightforward.

Magnesium also stabilizes the physical structure of DNA itself, but this effect depends on concentration. At normal levels, the mineral keeps DNA in its proper shape. At abnormally low levels, DNA becomes destabilized and more prone to breakage. Interestingly, at very high concentrations, magnesium can force DNA into unusual configurations that are also problematic.² The sweet spot is a normal physiological range, not too little, not too much.

Beyond DNA repair, magnesium influences p53, one of the most important tumor-suppressor proteins in the body. Laboratory research using atomic force microscopy found that magnesium ions significantly stimulate p53 binding to DNA, which is how p53 does its job of policing cells for damage.³ When p53 cannot bind properly, damaged cells are more likely to survive and replicate, a key step toward tumor formation.

Magnesium and the Immune Response to Tumors

One of the more striking findings in recent years comes from research on how the immune system fights cancer. A 2022 study published in Cell showed that CD8+ T cells, the immune cells that directly kill tumor cells, depend on magnesium to function properly. The mineral is sensed through a surface molecule called LFA-1, which T cells use to latch onto their targets. When magnesium levels in the surrounding fluid are low, LFA-1 does not work well, and T cells lose their ability to grip and destroy tumor cells.⁴

This matters for cancer immunotherapy, which relies on boosting those same T cells. If a patient is magnesium-deficient, their T cells may respond poorly to treatment. As one commentary on the research noted, dietary magnesium deficiency impairs T cell activity against tumors in ways that could undermine immunotherapy outcomes.⁵ Clinical trials testing whether magnesium supplementation improves immunotherapy response are still in early stages, but the biological rationale is compelling.

What Population Studies Show for Specific Cancers

The strongest dietary evidence connects magnesium to colorectal cancer. Multiple meta-analyses, each pooling data from hundreds of thousands of participants, have found that people with higher magnesium intake have a lower risk of developing colorectal cancer, with the benefit concentrated in colon cancer rather than rectal cancer. One meta-analysis of eight prospective studies found that those with the highest magnesium intake had roughly an 11% lower risk of colorectal cancer compared to those with the lowest intake.⁶ Another analysis found a roughly 20% lower risk and showed the relationship was nonlinear: the biggest drop in risk came when people went from very low magnesium intake to moderate levels, with diminishing returns beyond that.⁷ A third meta-analysis that included both cohort and case-control studies confirmed the pattern, finding about a 20% reduced risk of colorectal cancer among those with the highest magnesium intake in cohort data.⁸

For pancreatic cancer, the evidence is thinner but suggestive. A large U.S. cohort study found that people whose magnesium intake fell below 75% of the recommended daily allowance had a 76% higher rate of pancreatic cancer compared to those who met the recommendation.⁹ However, a large European cohort study found no overall association between magnesium intake and pancreatic cancer risk, only a borderline hint of benefit in overweight men.¹⁰ The discrepancy may reflect differences in how magnesium intake was measured, population characteristics, or the fact that pancreatic cancer is relatively rare and harder to study in observational data.

Breast cancer has also attracted attention. A study of over 1,700 women found that higher dietary magnesium was associated with about a 20% lower risk of breast cancer after adjusting for dietary factors, with a clear trend of decreasing risk as intake rose. The association was strongest among premenopausal women.¹¹ Among women already diagnosed with breast cancer, a separate study found that those in the highest third of dietary magnesium intake had about half the risk of dying from any cause compared to those in the lowest third, an association that was particularly strong in postmenopausal women.¹²

For prostate cancer, the picture is muddier. Some studies have suggested lower magnesium is linked to higher prostate cancer risk, while a study specifically designed to test this in Black and white men found that neither blood magnesium nor dietary intake was associated with prostate cancer risk in either group.¹³ A more recent study using a composite “magnesium depletion score” did find a link, but the authors themselves acknowledged the contradictory evidence.¹⁴ This is an area where the evidence genuinely does not point in a single direction.

The Calcium-to-Magnesium Ratio

One reason magnesium research gets complicated is that the mineral does not act alone. Its relationship with calcium turns out to be surprisingly important. The ratio of calcium to magnesium in your diet appears to modify how both minerals affect cancer risk and survival, and getting this ratio wrong may matter more than getting the absolute amount of either mineral wrong.

A large population-based cohort study found that among people whose calcium-to-magnesium ratio was below about 1.7, higher magnesium intake was actually associated with increased mortality from colorectal cancer, a finding that runs counter to the general trend.¹⁵ Meanwhile, data from a major cancer screening trial showed that calcium’s protective effect against advanced colorectal growths was strongest when the calcium-to-magnesium ratio fell between 1.7 and 2.5.¹⁶ The same ratio influenced whether physical activity reduced cancer mortality. Exercise was associated with about a 50% lower risk of cancer death only in people whose calcium-to-magnesium ratio was below 2.6.¹⁷

What this means practically: loading up on calcium supplements while ignoring magnesium, which is common, may actually blunt the health benefits of both minerals. Many Western diets are already calcium-heavy and magnesium-poor, so the ratio can drift well above the apparent sweet spot.

Magnesium During Cancer Treatment

Even if magnesium’s role in cancer prevention remains partly uncertain, its role during cancer treatment is well established and clinically urgent. Two of the most widely used categories of cancer drugs directly deplete magnesium.

Cisplatin, a platinum-based chemotherapy drug used against many solid tumors, damages the kidneys in ways that cause magnesium wasting. A 2025 study in JAMA Oncology analyzed nearly 14,000 patients and found that giving intravenous magnesium alongside cisplatin reduced the odds of acute kidney injury by about 20%.¹⁸ A smaller randomized trial went further, showing that preloading magnesium before cisplatin dramatically reduced the rate of a more chronic form of kidney damage, from about 47% in the control group to about 7% in the magnesium group.¹⁹

Anti-EGFR antibodies like cetuximab and panitumumab, used primarily in colorectal cancer, cause a different problem. They block a receptor in the kidney that is responsible for reabsorbing about 70% of filtered magnesium. The result is that patients essentially urinate out their magnesium. Early reports found that among patients tested, some developed severely low levels, and the mechanism was traced to this kidney-level interference.²⁰ How to optimally manage this side effect remains an open question in oncology, as magnesium wasting often worsens over the course of treatment.²¹

The Inflammation Connection

Chronic low-grade inflammation is a recognized driver of several cancers, and magnesium has long been proposed as an anti-inflammatory nutrient. The reality from clinical trials is more nuanced than the popular narrative suggests. A systematic review of randomized trials found that magnesium supplements did not significantly lower C-reactive protein, a common marker of inflammation, in the overall population.²² A separate meta-analysis reached the same conclusion for CRP and also found no significant effect on two other inflammatory markers, IL-6 and TNF-alpha.²³

There is an important caveat, though. When the first meta-analysis looked only at people who already had elevated inflammation, meaning CRP levels above 3 mg/L, magnesium supplementation did produce a meaningful drop. In the broader, less-inflamed population, the supplements had no measurable effect. This suggests magnesium may help calm inflammation that is already running high but does little in people whose inflammation is normal to begin with. For cancer relevance, this distinction matters: people with chronic conditions that fuel both inflammation and cancer risk might benefit most.

Magnesium Levels and Prognosis After Diagnosis

A growing number of studies are looking not just at whether magnesium prevents cancer, but at whether magnesium status affects outcomes for people who already have it. A 2025 analysis of two large U.S. cohorts found that cancer survivors with high magnesium depletion scores had roughly 2.5 times the risk of dying from any cause and about twice the risk of dying from cancer specifically, compared to those with no signs of depletion.²⁴

In specific cancers, the pattern holds. A study of patients with diffuse large B-cell lymphoma, the most common aggressive lymphoma, found that those with serum magnesium below 2.0 mg/dL had shorter survival than those above that threshold, with median overall survival of about 11 years versus about 13 years.²⁵ In locally advanced gastric cancer, low preoperative serum magnesium was an independent predictor of worse overall and disease-free survival for patients receiving immunochemotherapy.²⁶

The connection between magnesium, vitamin D, and survival has also been explored. Among colorectal cancer patients, the lowest mortality was seen in those who had both sufficient vitamin D levels and high magnesium intake, cutting the risk of death nearly in half compared to patients who were deficient in both.²⁷ This makes biological sense: magnesium is required for the enzymes that activate vitamin D in the body, so being short on one can effectively create a deficiency of the other.

Why Measuring Magnesium Status Is Harder Than It Sounds

One reason magnesium research is messier than you might expect is that the mineral is genuinely hard to measure. Most of your body’s magnesium lives inside cells and bones, not in the blood. A standard blood test measures serum magnesium, but that represents less than 1% of your total stores. You can be significantly depleted and still have a blood level that looks normal.²⁸ No single test can accurately capture your total magnesium status. Severe deficiency, with serum levels below about 0.75 mmol/L, is reliably detectable, but the gray zone between that threshold and adequacy is where most of the action probably lies and where testing is least reliable.²⁹

This measurement problem likely explains some of the contradictory findings across studies. Research that relies on dietary questionnaires to estimate magnesium intake captures a different slice of the picture than studies measuring blood levels, and neither fully reflects what is happening inside cells. It also means that individuals cannot easily learn whether they are in the range where magnesium might matter most for cancer risk.

The TRPM7 Channel and Tumor Cell Behavior

While most of the discussion so far has been about whether having enough magnesium is protective, there is a flipside. Cancer cells themselves use magnesium, and they have their own mechanisms for grabbing it. A magnesium-permeable ion channel called TRPM7 has emerged as a focus of research, particularly in breast cancer. TRPM7 is overexpressed in breast tumors, and it regulates signaling pathways that promote cell survival, growth, migration, and invasion.³⁰ Researchers are investigating whether blocking this channel could slow tumor progression.³¹

This creates an apparent paradox: magnesium deficiency seems to raise cancer risk, but established tumors may exploit magnesium transport for their own benefit. The resolution probably lies in timing and context. In healthy tissue, adequate magnesium supports DNA repair and immune surveillance, both of which prevent cancer from starting. Once a tumor has formed, it co-opts nutrient channels for growth. This is a pattern seen across cancer biology with many nutrients, not something unique to magnesium.

Widespread Deficiency and the Safety Margin

A complicating factor in all of this is that magnesium deficiency is extremely common. The magnesium content of fruits and vegetables has dropped over the past 50 years, and food processing strips out roughly 80% of the mineral, meaning a large proportion of people worldwide do not meet minimum daily requirements.³² Modern dietary patterns that are low in whole grains and vegetables, combined with soil depletion from intensive farming and the growing prevalence of chronic diseases that affect magnesium absorption, have made this a global issue rather than a niche concern.³³

For most healthy people, the safest path is dietary. Green leafy vegetables, nuts, seeds, legumes, and whole grains are the richest food sources. Supplements are widely available and generally well tolerated, but they are not without risk at extreme doses. In critically ill cancer patients with reduced kidney function, excess magnesium from medications like laxatives, antacids, or intravenous infusions can push levels dangerously high, a condition called hypermagnesemia that adds to complications and can increase mortality.³⁴ Healthy kidneys clear excess magnesium efficiently, so this concern applies mainly to people whose kidney function is already compromised. For someone undergoing cancer treatment, where kidney damage from chemotherapy is a real possibility, magnesium supplementation should be guided by an oncologist who can monitor levels and adjust doses accordingly.